The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.
 
Claudio Zanna
Employment - Debiopharm Group
 
Anne Vaslin
Employment - Debiopharm Group
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Bayer; Novartis
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Novartis
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim; Momenta Pharmaceuticals
Research Funding - Celgene; Debiopharm Group; Exelixis; Genentech/Roche; GlaxoSmithKline; Mirati Therapeutics; Peregrine Pharmaceuticals; Sanofi
 
Cinta Hierro
No Relationships to Disclose
 
Jeffrey G Supko
Employment - Sanofi (I)
Consulting or Advisory Role - Debiopharm Group; Millennium
 
Kiyohiko Nakai
Employment - Chugai Pharma
 
Nobuya Ishii
Employment - Chugai Pharma
 
Annick Menetrey
Employment - Debiopharm Group
 
Marie-Claude Roubaudi-Fraschini
Employment - Debiopharm Group
 
Julien Cordier
Employment - Debiopharm Group
 
Jerome Douchain
Employment - Debiopharm Group
 
Valerie Nicolas-Metral
Employment - Debiopharm Group
Patents, Royalties, Other Intellectual Property - Debiopharm Group